HeartRhythm

DECEMBER 31, 2024

Curtain etal1 performed an analysis of the VALIANT (Valsartan in Acute Myocardial Infarction) and PARADISE-MI (Prospective ARNi vs ACE Inhibitor Trial to Determine Superiority in Reducing Heart Failure Events After MI) trials to evaluate whether risk of sudden cardiac arrest (SCA) following acute myocardial infarction (MI) has changed over time.

Cardiac Arrest 79

Cardiac Arrest ACE Inhibitor Myocardial Infarction Heart Failure 79

American College of Cardiology

MARCH 6, 2024

The goal of the PARADISE-MI trial was to assess the efficacy and safety of sacubitril/valsartan compared with ramipril in a contemporary acute myocardial infarction (AMI) population.

ACE Inhibitor 48

ACE Inhibitor Myocardial Infarction Heart Failure Article 48

JAMA Cardiology

AUGUST 6, 2024

This secondary analysis of the Valsartan in Acute Myocardial Infarction (VALIANT) and Prospective ARNi vs ACE Inhibitor Trial to Determine Superiority in Reducing Heart Failure Events After MI (PARADISE-MI) randomized clinical trials investigates the changes over time in sudden death rate after myocardial infarction and the characteristics of people (..)

Myocardial Infarction 90

Myocardial Infarction ACE Inhibitor Heart Failure 90

DAIC

APRIL 6, 2024

However, researchers said the drug may be helpful in reducing heart failure risks, including hospitalization, following a heart attack. The study enrolled 6,522 people treated for acute myocardial infarction at 451 centers in 22 countries.

Heart Attack 98

Heart Attack Heart attacks Heart Failure Outpatient 98

European Journal of Heart Failure

NOVEMBER 29, 2023

Sacubitril/valsartan and a mineralocorticoid receptor anatogonist (MRA) can be initiated safely and used simultaneously in post-myocardial infarction complicated by left ventricular (LV) dysfunction, congestion or both – Insight from the PARADISE MI trial. Safety was defined as symptomatic hypotension, hyperkalaemia >5.5 mmol/L,

Myocardial Infarction 40

Myocardial Infarction ACE Inhibitor Heart Failure Pulmonary 40

DAIC

APRIL 6, 2024

While composite of death and heart failure hospitalizations was not significantly reduced, empagliflozin may help reduce heart failure risks after a heart attack, according to results from the EMPACT-MI trial presented on day one of the American College of Cardiology Scientific Sessions, ACC.24,

Heart Attack 81

Heart Attack Heart attacks Heart Failure Outcomes 81